An Open label, Single Center, prospective interventional, phase II clinical trial to evaluate the Efficacy and Safety of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine(BV-AVD) combination escalation in advanced stage classical Hodgkin lymphoma patients who did not achieve interim Positron Emission Tomography (PET2) negativity (defined as Deauville score 3 or less) after 2 cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD)

drug protocol number

drug sponsor

King Faisal Specialist Hospital & Research Centre Riyadh, Saudi Arabia

drug study

BRENTUXIMAB VEDOTIN, DACARBAZINE, VINBLASTINE, DOXORUBICIN HYDROCHLORIDE

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh)

drug status

Rejected

drug phase